Subtype
Autonomic Nervous System Neoplasm
CI-CAN-00000468Explore in graph →
Non-malignant32 active trials3 evidence items
- NCIt
- C5112
Loading cancer entity…
Subtype
CI-CAN-00000468Explore in graph →
Clinical trials
148 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05885399 | The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment | unknown | Phase 2 | 5 | Peking Union Medical College HospitalOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05885386 | A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05883085 | A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL | unknown | Phase 2 | 10 | Peking Union Medical College HospitalOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT00874614 | A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma | unknown | Phase 2 | 74 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 20, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Jun 2, 2023source: clinicaltrials